|
시장보고서
상품코드
1605880
종양성 골연화증 시장 : 시장 규모, 점유율, 동향, 산업 분석 보고서-치료 유형별, 최종 사용자별, 지역별-시장 예측(2025-2034년)Tumor-Induced Osteomalacia Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, End Users, and Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최근 조사에 따르면 종양성 골연화증 시장 규모는 2034년까지 1억 5,300만 달러에 이를 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학을 자세히 파악하여, 미래 시장 성장에 대한 분석을 제공합니다.
종양성 골연화증(TIO) 시장은 희귀한 뼈 질환에 대한 인식 증가, 진단 기술의 진보, 인산염 낭비 및 골 미네랄화 문제를 일으키는 다양한 종양과 관련된 TIO의 유병률의 상승에 의해 견인되고 있습니다. 이 시장은 표적 치료제와 새로운 치료법의 개발과 관련된 기회와이 질병의 효과적인 관리를 위한 연구 개발에 대한 투자 증가로부터 이익을 얻고 있습니다.
기대되는 시장 동향으로는 맞춤형 의료에 대한 주목, TIO를 보다 정확하게 특정해 치료하기 위한 유전자 및 분자 진단의 활용 등을 들 수 있습니다. 전체로서, 질환 메커니즘의 이해, 환자의 결과의 개선, 치료 옵션 파이프라인의 확대로 시장은 성장하고 있습니다.
종양성 골연화증 시장 보고서 하이라이트
치료 유형별 분석에서는 인산염의 보충과 표적 치료를 통해 병태를 관리하는데 있어서 중요한 역할을 하기 때문에 약제와 보충제 부문이 종양성 골연화증 시장을 독점하고 있습니다. 그러나 외과적 수술의 진보와 종양 절제에 대한 주력 증가로 수술이 중요한 성장 분야로 견인력을 증가하고 있습니다.
최종 사용자별 분석에서 병원은 TIO의 진단 및 치료의 주요 장소로 시장을 선도하고 있으며, 종합적인 관리 및 전문 장비를 제공합니다. 외래수술센터는 저침습 수술의 발전과 외래치료에 대한 환자의 선호도가 높아지면서 급속한 성장을 이루고 있습니다.
북미는 TIO 시장에서 지배적인 지역이지만, 이는 고급 헬스케어 인프라와 다액의 연구투자에 기인합니다. 아시아 태평양은 가장 성장률이 높은 지역으로 헬스케어 시설 개선, 인지도 향상, 환자 수 증가가 그 요인입니다.
종양성 골연화증(TIO) 시장에 적극적으로 관여하는 주요 기업은 Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd., Eli Lilly and Company, Amgen Inc., Novartis AG, Sanofi SA, Pfizer Inc., AbbVie Inc., and Horizon Therapeutics. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 종양성 골연화증 시장 인사이트
- 시장 현황
- 종양성 골연화증 시장 역학
- 성장 촉진요인 및 기회
- 표적 요법에 대한 주목 고조
- 희소질환에 대한 인식과 진단의 향상
- 억제요인 및 과제
- 고액의 치료비
- 성장 촉진요인 및 기회
- PESTEL 분석
- 종양성 골연화증 시장의 용도 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 종양성 골연화증 시장 : 치료 유형별
- 주요 조사 결과
- 서문
- 의약품 및 보충제
- 수술
제6장 세계의 종양성 골연화증 시장 : 최종 사용자별
- 주요 조사 결과
- 서문
- 병원
- 외래수술센터(ASC)
- 전문 클리닉
- 기타
제7장 세계의 종양성 골연화증 시장 : 지역별
- 주요 조사 결과
- 서문
- 종양성 골연화증 시장 평가 : 지역별(2020-2034년)
- 북미
- 북미 : 치료 유형별(2020-2034년)
- 북미 : 최종 사용자별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 치료 유형별(2020-2034년)
- 유럽 : 최종 사용자별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 치료 유형별(2020-2034년)
- 아시아태평양 : 최종 사용자별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 치료 유형별(2020-2034년)
- 중동 및 아프리카 : 최종 사용자별(2020-2034년)
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 치료 유형별(2020-2034년)
- 라틴아메리카 : 최종 사용자별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제8장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴, 협업, 합의 및 공개
제9장 기업 프로파일
- Ultragenyx Pharmaceutical Inc.
- Kyowa Kirin Co., Ltd.
- Eli Lilly and Company
- Amgen Inc.
- Novartis AG
- Sanofi SA
- Pfizer Inc.
- AbbVie Inc.
- Horizon Therapeutics
The tumor-induced osteomalacia market size is expected to reach USD 153.00 million by 2034, according to a new study by Polaris Market Research. The report "Tumor-Induced Osteomalacia Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Drugs & Supplements and Surgery), End Users (Hospitals, Ambulatory Surgery Centers, Speciality Clinics, and Others), and Region (North America, Europe, Asia Pacific, Latin America and the Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The tumor-induced osteomalacia (TIO) market is driven by increasing awareness of rare bone disorders, advancements in diagnostic techniques, and the rising prevalence of TIO, which is linked to various tumours causing phosphate wasting and bone mineralisation issues. The market benefits from opportunities related to the development of targeted therapies and novel treatments, as well as the growing investment in research for effective management of the condition.
Expected market trends include a focus on personalised medicine and the utilisation of genetic and molecular diagnostics to identify and treat TIO more accurately. Overall, the market is experiencing growth due to enhanced understanding of the disease mechanisms, improving patient outcomes, and the expanding pipeline of therapeutic options.
Tumor-Induced Osteomalacia Market Report Highlights
By treatment type analysis, the drugs and supplements segment dominates the tumor-induced osteomalacia market due to their crucial role in managing the condition through phosphate replacement and targeted therapies. However, surgery is gaining traction as a significant growth area with advancements in surgical techniques and increased focus on tumour resection.
By end users analysis, the hospitals lead the market as the primary setting for TIO diagnosis and treatment, offering comprehensive care and specialised equipment. Ambulatory surgery centers are experiencing rapid growth, driven by advancements in minimally invasive procedures and increasing patient preference for outpatient care.
North America is the dominant region in the TIO market, attributed to advanced healthcare infrastructure and significant research investments. Asia Pacific is the highest-growing region, driven by improving healthcare facilities, increasing awareness, and a growing patient population.
Key players actively involved in the tumor-induced osteomalacia (TIO) market include Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd., Eli Lilly and Company, Amgen Inc., Novartis AG, Sanofi S.A., Pfizer Inc., AbbVie Inc., and Horizon Therapeutics.
Polaris market research has segmented the tumor-induced osteomalacia market report based on treatment type, end users, and region:
By Treatment Type Outlook (Revenue - USD Million, 2020-2034)
- Drugs & Supplements
- Surgery
By End Users Outlook (Revenue - USD Million, 2020-2034)
- Hospitals
- Ambulatory Surgery Centers
- Speciality Clinics
- Others
By Regional Outlook (Revenue - USD Million, 2020-2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Tumor-Induced Osteomalacia Market Insights
- 4.1. Tumor-Induced Osteomalacia Market - Market Snapshot
- 4.2. Tumor-Induced Osteomalacia Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Focus on Targeted Therapies
- 4.2.1.2. Rising Awareness and Diagnosis of Rare Diseases
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Treatment Costs
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Tumor-Induced Osteomalacia Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Tumor-Induced Osteomalacia Market, by Treatment Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 5.3. Drugs & Supplements
- 5.3.1. Global Tumor-Induced Osteomalacia Market, by Drugs & Supplements, by Region, 2020-2034 (USD Million)
- 5.4. Surgery
- 5.4.1. Global Tumor-Induced Osteomalacia Market, Surgery, by Region, 2020-2034 (USD Million)
6. Global Tumor-Induced Osteomalacia Market, by End User
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 6.3. Hospitals
- 6.3.1. Global Tumor-Induced Osteomalacia Market, by Hospitals, by Region, 2020-2034 (USD Million)
- 6.4. Ambulatory Surgery Centers
- 6.4.1. Global Tumor-Induced Osteomalacia Market, by Ambulatory Surgery Centers, by Region, 2020-2034 (USD Million)
- 6.5. Speciality Clinics
- 6.5.1. Global Tumor-Induced Osteomalacia Market, by Speciality Clinics, by Region, 2020-2034 (USD Million)
- 6.6. Others
- 6.6.1. Global Tumor-Induced Osteomalacia Market, by Others, by Region, 2020-2034 (USD Million)
7. Global Tumor-Induced Osteomalacia Market, by Geography
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Tumor-Induced Osteomalacia Market Assessment, By Geography, 2020-2034 (USD Million)
- 7.3. Tumor-Induced Osteomalacia Market - North America
- 7.3.1. North America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.3.2. North America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.3.3. Tumor-Induced Osteomalacia Market - U.S.
- 7.3.3.1. U.S.: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.3.3.2. U.S.: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.3.4. Tumor-Induced Osteomalacia Market - Canada
- 7.3.4.1. Canada: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.3.4.2. Canada: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4. Tumor-Induced Osteomalacia Market - Europe
- 7.4.1. Europe: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.2. Europe: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.3. Tumor-Induced Osteomalacia Market - UK
- 7.4.3.1. UK: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.3.2. UK: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.4. Tumor-Induced Osteomalacia Market - France
- 7.4.4.1. France: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.4.2. France: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.5. Tumor-Induced Osteomalacia Market - Germany
- 7.4.5.1. Germany: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.5.2. Germany: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.6. Tumor-Induced Osteomalacia Market - Italy
- 7.4.6.1. Italy: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.6.2. Italy: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.7. Tumor-Induced Osteomalacia Market - Spain
- 7.4.7.1. Spain: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.7.2. Spain: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.8. Tumor-Induced Osteomalacia Market - Netherlands
- 7.4.8.1. Netherlands: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.8.2. Netherlands: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.9. Tumor-Induced Osteomalacia Market - Russia
- 7.4.9.1. Russia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.9.2. Russia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.4.10. Tumor-Induced Osteomalacia Market - Rest of Europe
- 7.4.10.1. Rest of Europe: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.4.10.2. Rest of Europe: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5. Tumor-Induced Osteomalacia Market - Asia Pacific
- 7.5.1. Asia Pacific: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.2. Asia Pacific: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.3. Tumor-Induced Osteomalacia Market - China
- 7.5.3.1. China: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.3.2. China: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.4. Tumor-Induced Osteomalacia Market - India
- 7.5.4.1. India: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.4.2. India: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.5. Tumor-Induced Osteomalacia Market - Malaysia
- 7.5.5.1. Malaysia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.5.2. Malaysia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.6. Tumor-Induced Osteomalacia Market - Japan
- 7.5.6.1. Japan: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.6.2. Japan: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.7. Tumor-Induced Osteomalacia Market - Indonesia
- 7.5.7.1. Indonesia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.7.2. Indonesia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.8. Tumor-Induced Osteomalacia Market - South Korea
- 7.5.8.1. South Korea: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.8.2. South Korea: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.9. Tumor-Induced Osteomalacia Market - Australia
- 7.5.9.1. Australia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.9.2. Australia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.5.10. Tumor-Induced Osteomalacia Market - Rest of Asia Pacific
- 7.5.10.1. Rest of Asia Pacific: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.5.10.2. Rest of Asia Pacific: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6. Tumor-Induced Osteomalacia Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.2. Middle East & Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.3. Tumor-Induced Osteomalacia Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.3.2. Saudi Arabia: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.4. Tumor-Induced Osteomalacia Market - UAE
- 7.6.4.1. UAE: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.4.2. UAE: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.5. Tumor-Induced Osteomalacia Market - Israel
- 7.6.5.1. Israel: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.5.2. Israel: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.6. Tumor-Induced Osteomalacia Market - South Africa
- 7.6.6.1. South Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.6.2. South Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.6.7. Tumor-Induced Osteomalacia Market - Rest of Middle East & Africa
- 7.6.7.1. Rest of Middle East & Africa: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.6.7.2. Rest of Middle East & Africa: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.7. Tumor-Induced Osteomalacia Market - Latin America
- 7.7.1. Latin America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.2. Latin America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.7.3. Tumor-Induced Osteomalacia Market - Mexico
- 7.7.3.1. Mexico: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.3.2. Mexico: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.7.4. Tumor-Induced Osteomalacia Market - Brazil
- 7.7.4.1. Brazil: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.4.2. Brazil: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.7.5. Tumor-Induced Osteomalacia Market - Argentina
- 7.7.5.1. Argentina: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.5.2. Argentina: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
- 7.7.6. Tumor-Induced Osteomalacia Market - Rest of Latin America
- 7.7.6.1. Rest of Latin America: Tumor-Induced Osteomalacia Market, by Treatment Type, 2020-2034 (USD Million)
- 7.7.6.2. Rest of Latin America: Tumor-Induced Osteomalacia Market, by End User, 2020-2034 (USD Million)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Ultragenyx Pharmaceutical Inc.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Kyowa Kirin Co., Ltd.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Eli Lilly and Company
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Amgen Inc.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Novartis AG
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Sanofi S.A.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Pfizer Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. AbbVie Inc.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Horizon Therapeutics
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
